Sarcomatoid Differentiation as a Predictor of Recurrence in Intermediate- and High-Risk RCC: Implications for...

Area of Science:

• Oncology
• Urology
• Nephrology

Background:

• Adjuvant pembrolizumab enhances survival for high-risk clear cell renal cell carcinoma (ccRCC).
• Broad application risks overtreatment; sarcomatoid differentiation is a prognostic factor not currently used for adjuvant decisions.

Purpose of the Study:

• To determine if sarcomatoid differentiation can refine patient selection for adjuvant immunotherapy in intermediate- and high-risk ccRCC.
• To evaluate the clinical utility and cost-effectiveness of using sarcomatoid differentiation to guide treatment decisions.

Main Methods:

• Retrospective analysis of 136 ccRCC patients meeting modified KEYNOTE-564 criteria.
• Analysis of recurrence-free survival (RFS) using Kaplan-Meier, logistic regression, and Cox models.
• Assessment of clinical utility via number needed to treat (NNT) and cost-effectiveness modeling.

Main Results:

• Sarcomatoid differentiation significantly correlated with recurrence (HR=2.31, P=.042).
• Intermediate-risk patients with sarcomatoid features had higher recurrence (50.0% vs 16.7%, P=.007).
• Selective treatment based on sarcomatoid status improved NNT from 5 to 2 and could save $11.4 million USD.

Conclusions:

• Sarcomatoid differentiation is an independent predictor of recurrence in ccRCC.
• Selective immunotherapy guided by sarcomatoid status may optimize adjuvant treatment decisions.
• This approach can potentially avoid overtreatment and improve patient outcomes.